SGHTSGHTHealthcare · Medical Devices

SGHT Stock Forecast: Sight Sciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$10
−4.14% on the day

The 8 Wall Street analysts covering Sight Sciences, Inc. hold a median 12-month price target of $13 — +25.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 85 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$590.2M
Ticker Nerd rank
85/ 100
Median analyst target
$13
Analysts covering
8
Revenue$23.4M+19.5% y/y
Operating income−$3.9M
Net income−$4.4M
Free cash flow−$5.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.0%
1M
+18.1%
YTD
+28.4%
1Y
+53.3%
From 52W high
−7.5%
From 52W low
+195.1%
$3
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Sight Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
85/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Growth
92
Accruals
80
Quality
75
Revisions
62
Value
57
Issuance
29
Volatility
25

Momentum (98): The shares have been drifting up relative to others.

Volatility (25): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SGHT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SGHT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26SGHTHigh $14Median $13Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
6
Buy
2
Hold
0
Sell
$10
Low
$13
Median
$14
High

The green dot is the last close — the median target sits +25.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
12 Nov 2026UBSMaintainsBuy$8.00 → $14
5 Nov 2026Piper SandlerReiteratesOverweight$9.00 → $12
15 Oct 2026HC Wainwright & Co.InitiatesBuy$14
5 Oct 2026CitigroupMaintainsNeutral$8.00 → $10
17 Aug 2026CitigroupMaintainsNeutral—
6 Aug 2026UBSMaintainsBuy$7.00 → $8.00
28 July 2026UBSAssumesBuy$11 → $7.00
8 July 2026CitigroupMaintainsNeutral$5.15 → $6.00
28 May 2026CitigroupMaintainsNeutral—
6 Mar 2026CitigroupMaintainsNeutral—
6 Mar 2026UBSMaintainsBuy—
2 Mar 2026StifelMaintainsBuy—
5 Jan 2026Piper SandlerUpgradeOverweight—
23 Dec 2025UBSMaintainsBuy—
11 Dec 2025CitigroupMaintainsNeutral—
10 Dec 2025Lake StreetMaintainsBuy—
2 Dec 2025Morgan StanleyMaintainsEqual-Weight—
10 Nov 2025Morgan StanleyMaintainsEqual-Weight—
7 Nov 2025Piper SandlerMaintainsNeutral—
21 Oct 2025Lake StreetMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SGHT.

Market Radar

This page is one stock. Monday covers all of them.

SGHT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SGHT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Sight Sciences, Inc. returned +53.3% against +6.9% for the S&P 500, dividends included.

SGHT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160180Jan 26Apr 26Jul 26Oct 26SGHTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SGHT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
6.3×

Cheaper than 17% of US stocks

Price / book
11.3×

Cheaper than 6% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
91.4%

Higher than 97% of US stocks

Operating margin
−20.2%

Higher than 22% of US stocks

Net margin
−32.1%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−50.1%

Higher than 22% of US stocks

Return on assets
−10.1%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sight Sciences, Inc. has a market value of $590.2M and an enterprise value of $555.0M.

  • Revenue in the twelve months to 30 June 2026: $83.4M. The latest quarter grew 19.5% year on year.

  • Net income over the same four quarters: −$29.8M, a −35.7% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.56.

  • Free cash flow in the twelve months to 30 June 2026: −$23.3M.

  • Shares outstanding: 54.7M.

  • Sight Sciences, Inc. employs 186 people — $448K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

SGHT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SGHTSight Sciences, Inc.$590.2M85
QDELQuidelOrtho Corp.$567.3M48
TCMDTactile Systems Technology, Inc.$577.4M97
PACBPacific Biosciences of California, Inc.$492.3M68
AVRAnteris Technologies Global Corp.$485.2M25
RCELAVITA Medical, Inc.$483.1M85
DCTHDelcath Systems, Inc.$648.7M98

Take a look at SGHT’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Sight Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SGHT

What is the SGHT stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Sight Sciences, Inc. have a median 12-month price target of $13, with estimates ranging from $10 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SGHT stock a buy right now?

Of the 8 analysts covering Sight Sciences, Inc., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sight Sciences, Inc. 85 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SGHT?

As at 21 Nov 2026, Sight Sciences, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will SGHT stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +25.2% from the last close, and Ticker Nerd's factor model ranks Sight Sciences, Inc. 85 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SGHT stock forecast for 2030?

No analyst covering Sight Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGHT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $14 over the next 12 months.

How has SGHT stock performed over the past year?

Sight Sciences, Inc. returned +53.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sight Sciences, Inc. do?

Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing interventional technologies for glaucoma and dry eye disease. Its current product portfolio includes the OMNI Surgical System family for minimally invasive glaucoma procedures, the SION Surgical Instrument for trabecular meshwork excision, and the TearCare System for treating evaporative dry eye associated with meibomian gland dysfunction.

Company

About Sight Sciences, Inc.

Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing interventional technologies for glaucoma and dry eye disease. Its current product portfolio includes the OMNI Surgical System family for minimally invasive glaucoma procedures, the SION Surgical Instrument for trabecular meshwork excision, and the TearCare System for treating evaporative dry eye associated with meibomian gland dysfunction. The company serves eyecare providers, including ophthalmologists and optometrists, by offering tools designed to address key causes of intraocular pressure buildup and tear-film dysfunction. Sight Sciences operates through its Surgical Glaucoma and Dry Eye segments, positioning its products across procedural eyecare settings where device-based treatment options are used to support patient care. Headquartered in Menlo Park, California, Sight Sciences plays a focused role in the medical technology market by supplying specialized devices for prevalent eye conditions.

CEO Mr. Paul Badawi · 186 employees · United States · https://www.sightsciences.com